Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy

Current Opinion in Obstetrics and Gynecology

Volumn 23, Issue 1, 2011, Pages 24-30

  Tsujioka, Hiroshi ^a   Yotsumoto, Fusanori ^a   Hikita, Shoko ^a   Ueda, Taeko ^a   Kuroki, Masahide ^a   Miyamoto, Shingo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

cancer; epidermal growth factor receptor; heparin binding epidermal growth factor like growth factor; targeted therapy

Indexed keywords

AMPHIREGULIN; CETUXIMAB; DIPHTHERIA TOXOID CRM197; DISINTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA; TRASTUZUMAB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; COMPETITIVE INHIBITION; DIMERIZATION; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BACTERIAL PROTEINS; CELL PROLIFERATION; CLINICAL TRIALS, PHASE I AS TOPIC; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYSOPHOSPHOLIPIDS; OVARIAN NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 78651437402     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3283409c91     Document Type: Article

References (54)

1. Penson RT, Shannon KE, Sharpless NE, Seiden MV. Ovarian cancer: an update on genetics and therapy. Compr Ther 1998; 24:477-487. (Pubitemid 28478227)
2. Mills GB, May C, McGill M, et al. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res 1988; 48:1066-1071. (Pubitemid 18075508)
3. Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 2006; 7:925-934. (Pubitemid 44615952)
4. Westermann AM, Havik E, Postma FR, et al. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 1998; 9:437-442. (Pubitemid 28273038)
5. Xu Y, Gaudette DC, Boynton JD, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1995; 1:1223-1232.
6. Moolenaar WH, Kranenburg O, Postma FR, Zondag GC. Lysophosphatidic acid: G-protein signalling and cellular responses. Curr Opin Cell Biol 1997; 9:168-173. (Pubitemid 27135983)
7. Fang X, Schummer M, Mao M, et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 2002; 23:257-264. (Pubitemid 34634137)
8. Goetzl EJ, Lee H, Dolezalova H, et al. Mechanisms of lysolipid phosphate effects on cellular survival and proliferation. Ann N Y Acad Sci 2000; 905:177-187. (Pubitemid 30255417)
9. Xu Y, Shen Z, Wiper DW, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998; 280: 719-723. (Pubitemid 28405297)
10. Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-proteincoupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402:884-888. (Pubitemid 30017171)
11. Hirata M, Umata T, Takahashi T, et al. Identification of serum factor inducing ectodomain shedding of proHB-EGF and studies of noncleavable mutants of proHB-EGF. Biochem Biophys Res Commun 2001; 283:915-922. (Pubitemid 32924667)
12. Gschwind A, Hart S, Fischer OM, Ullrich A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J 2003; 22:2411-2421. (Pubitemid 36604980)
13. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411:355-365. (Pubitemid 32467045)
14. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factorrelated peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.
15. Normanno N, Bianco C, De Luca A, et al. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003; 10:1-21. (Pubitemid 36457237)
16. Scambia G, Benedetti Panici P, Battaglia F, et al. Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol 1992; 10:529-535.
17. Gangarosa LM, Sizemore N, Graves-Deal R, et al. A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. J Biol Chem 1997; 25:18926-18931 (Pubitemid 27318245)
18. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26:3291-3310. (Pubitemid 46763022)
19. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366:2-16. (Pubitemid 43199589)
20. Miyamoto S, Hirata M, Yamazaki A, et al. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 2004; 64:5720-5727. (Pubitemid 39095570)
21. Tanaka Y, Miyamoto S, Suzuki SO, et al. Clinical significance of heparinbinding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 2005; 11:4783-4792. (Pubitemid 41557199)
22. Yotsumoto F, Yagi H, Suzuki SO, et al. Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun 2008; 365:555-561. (Pubitemid 350181687)
23. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19:3159-3167.
24. Ferguson KM, Berger MB, Mendrola JM, et al. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 2003; 11:507-517.
25. Cho HS, Leahy DJ. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 2002; 297:1330-1333.
26. Burgess AW, Cho HS, Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003; 12:541-552. (Pubitemid 37222478)
27. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9:463-475.
28. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001; 2:127-137.
29. Berger MB, Mendrola JM, Lemmon MA. ErbB3/Her3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett 2004; 569:332-336.
30. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5:341-354.
31. Klos KS, Wyszomierski SL, Sun M, et al. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 2006; 66:2028-2037. (Pubitemid 43294911)
32. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7:505-516. (Pubitemid 44036456)
33. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006; 6:714-727. (Pubitemid 44286003)
34. Wang Q, Greene MI. Mechanisms of resistance to ErbB-targeted cancer therapeutics. J Clin Invest 2008; 118:2389-2392. (Pubitemid 351949768)
35. Zeineldin R, Muller CY, Stack MS, Hudson LG. Targeting the EGF receptor for ovarian cancer therapy. J Oncol 2010. doi:10.1155/2010/414676.
36. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. Clin Invest 2008; 118:2609-2619. (Pubitemid 351949788)
37. Klein S, Levitzki A. Targeting the EGFR and the PKB pathway in cancer. Curr Opin Cell Biol 2009; 21:185-193.
38. Miyamoto S, Yagi H, Yotsumoto F, et al. Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Sci 2006; 97:341-347.
39. Yotsumoto F, Sanui A, Fukami T, et al. Efficacy of ligand-based targeting for the EGF system in cancer. Anticancer Res 2009; 29:4879-4885.
40. Higashiyama S, Nanba D. ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. Biochim Biophys Acta 2005; 1751:110-117. (Pubitemid 41033299)
41. Higashiyama S, Abraham JA, Miller J, et al. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991; 251:936-939. (Pubitemid 21926188)
42. Izumi Y, Hirata M, Hasuwa H, et al. A metalloprotease-disintegrin MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J 1998; 17:7260-7272. (Pubitemid 29002695)
43. Seals DF, Coutneidges SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 1998; 17:7-30.
44. Takenobu H, Yamazaki A, Hirata M, et al. The stress-and inflammatory cytokine-induced ectodomain shedding of heparin-binding epidermal growth factor-like growth factor is mediated by p38 MAPK, distinct from the 12-Otetradecanoylphorbol-13-acetate-and lysophosphatidic acid-induced signaling cascades. J Biol Chem 2003; 278:17255-17262. (Pubitemid 36799607)
45. Koshikawa N, Mizushima H, Minegishi T, et al. Membrane type 1-matrix metalloproteinase cleaves off the NH2-terminal portion of heparin-binding epidermal growth factor and converts it into a heparin-independent growth factor. Cancer Res 2010; 70:6093-6103.
46. Nanba D, Mammoto A, Hashimoto K, Higashiyama S. Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. J Cell Biol 2003; 163:489-502. (Pubitemid 37429863)
47. Kinugasa Y, Hieda M, Hori M, Higashiyama S. The carboxyl-terminal fragment of pro-HB-EGF reverses Bcl6-mediated gene repression. J Biol Chem 2007; 282:14797-14806. (Pubitemid 47093367)
48. Lin J, Hutchinson L, Gaston SM, et al. BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparin-binding EGF-like growth factor: a unique role for proHB-EGF in cell survival regulation. J Biol Chem 2001; 276:30127-30132. (Pubitemid 37385092)
49. Yagi H, Miyamoto S, Tanaka Y, et al. Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br J Cancer 2005; 92:1737-1745. (Pubitemid 40756486)
50. Mitamura T, Higashiyama S, Taniguchi N, et al. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGFlike growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem 1995; 270:1015-1019.
51. Yagi H, Yotsumoto F, Miyamoto S. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol Cancer Ther 2008; 7:3441-3451.
52. Buzzi S, Rubboli D, Buzzi G, et al. CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunol Immunother 2004; 53:1041-1048. (Pubitemid 39371748)
53. Yagi H, Yotsumoto F, Sonoda K, et al. Synergistic antitumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer. Int J Cancer 2009; 124:1429-1439.
54. Lindzen M, Lavi S, Leitner O, Yarden Y. Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGFreceptor ligands. Proc Natl Acad Sci U S A 2010; 107:12559-12563.